Immunohistochemical (IHC) analysis was used to investigate the expression levels of PSMC2 in specimens of tumor acquired from 145 patients with prostate cancer; these data were then compared with the expression levels of PSMC2 in normal control tissues. Here, PSMC2 is linked to prostate carcinoma.